Andere talen Transcenta Holding Limited

Aandelen

6628

KYG9005B1041

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:20 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,78 ^HKD	+1,71%		+5,95%	-50,42%

09/04	Transcenta werkt samen met Agilent aan de ontwikkeling van Claudin18.2 Companion Diagnostic	MT
09/04	Transcenta Holding Limited kondigt samenwerking aan met Agilent Technologies voor de ontwikkeling van een Claudin18.2 Companion Diagnostic ter ondersteuning van TranStar301 wereldwijde fase III studie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic	09/04
Transcenta Holding Limited Announces Collaboration with Agilent Technologies to Develop a Claudin18.2 Companion Diagnostic to Support TranStar301 Global Phase III Trial	09/04
Transcenta Holding Limited Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Transcenta Publishes Promising Results of Anti-Tumor Drug's Efficacy and Safety in European Journal	13/12
Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging	13/12
Transcenta Presents Data on Gastric/Gastroesophageal Cancer Treatment Trial at Spain Oncology Meet	24-10-23
Transcenta Holding Limited Presents Updated Efficacy Data from the Expansion Cohort of the Transtar102 of Osemitamab Plus Capox Chemotherapy Study as the First-Line Treatment of Advanced G/Gej Cancer At the ESMO Congress 2023 in Madrid, Spain	23-10-23
US FDA Approves Phase 3 Trial for Transcenta's Gastric Cancer Treatment	04-10-23
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients	04-10-23
Transcenta Widens Loss in H1	23-08-23
Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023	22-08-23
Transcenta Holding Limited Reports Earnings Results for the Half Year Ended June 30, 2023	22-08-23
Transcenta Moves to Phase II Trial of Osteoporosis Drug	31-07-23
Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab)	31-07-23
China, South Korea Approve Transcenta's Phase 3 Trial for Anti-Tumor Medication	07-07-23
Transcenta Holding Limited Receives Approval from China CDE and South Korea MFDS to Initiate Transtar301 Global Phase III Pivotal Trial of Osemitamab	07-07-23
Transcenta Holding Limited Presents Pfs Data by Cldn18.2 Expression Level from Phase I/Ii Study of Osemitamab Plus Capecitabine and Oxaliplatin as the First-Line Treatment of Advanced G/Gej Cancer	30-06-23
Transcenta Holding Limited Announces Update on Efficacy Data of Osemitamab Plus Capecitabine and Oxaliplatin	30-06-23
Transcenta Holding Limited commences an Equity Buyback for 10% of its issued share capital, under the authorization approved on June 9, 2023.	09-06-23
Transcenta Holding Limited's Equity Buyback announced on September 14, 2022, has expired.	09-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Transcenta Holding Limited

Aandelen

6628

KYG9005B1041

Andere talen

Filters